HDAC5 Inhibitors as a Potential Treatment in Breast Cancer Affecting Very Young Women

Background: Breast cancer in very young women (BCVY) defined as <35 years old, presents with different molecular biology than in older patients. High HDAC5 expression has been associated with poor prognosis in breast cancer (BC) tissue. We aimed to analyze HDAC5 expression in BCVY and older patie...

Descripción completa

Detalles Bibliográficos
Autores: Oltra, SS, Cejalvo, JM, Tormo, E, Albanell, M, Ferrer, A, Nacher, M, Bermejo, B, Hernando, C, Chirivella, I, Alonso, E, Burgues, O, Pena-Chilet, M, Eroles, P, Lluch, A, Ribas, G, Martinez, MT
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2020
País:España
Institución:INCLIVA
Repositorio:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
OAI Identifier:oai:incliva.fundanetsuite.com:p4206
Acceso en línea:https://incliva.portalinvestigacion.com/publicaciones/4206
Access Level:acceso abierto
Palabra clave:breast cancer
young women
histone deacetylase
HDAC5 inhibitors
LMK-235
id ES_115cb6ec07a968c25d53d3092f4e633d
oai_identifier_str oai:incliva.fundanetsuite.com:p4206
network_acronym_str ES
network_name_str España
repository_id_str
spelling HDAC5 Inhibitors as a Potential Treatment in Breast Cancer Affecting Very Young WomenOltra, SSCejalvo, JMTormo, EAlbanell, MFerrer, ANacher, MBermejo, BHernando, CChirivella, IAlonso, EBurgues, OPena-Chilet, MEroles, PLluch, ARibas, GMartinez, MTbreast canceryoung womenhistone deacetylaseHDAC5 inhibitorsLMK-235Background: Breast cancer in very young women (BCVY) defined as <35 years old, presents with different molecular biology than in older patients. High HDAC5 expression has been associated with poor prognosis in breast cancer (BC) tissue. We aimed to analyze HDAC5 expression in BCVY and older patients and their correlation with clinical features, also studying the potential of HDAC5 inhibition in BC cell lines. Methods: HDAC5 expression in 60 BCVY and 47 older cases were analyzed by qRT-PCR and correlated with clinical data. The effect of the HDAC5 inhibitor, LMK-235, was analyzed in BC cell lines from older and young patients. We performed time and dose dependence viability, migration, proliferation, and apoptosis assays. Results: Our results correlate higher HDAC5 expression with worse prognosis in BCVY. However, we observed no differences between HDAC5 expression and pathological features. Our results showed greatly reduced progression in BCVY cell lines and also in all triple negative subtypes when cell lines were treated with LMK-235. Conclusions: In BCVY, we found higher expression of HDAC5. Overexpression of HDAC5 in BCVY correlates with lower survival rates. LMK-235 could be a potential treatment in BCVY.MDPI2020info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://incliva.portalinvestigacion.com/publicaciones/4206CancersISSN: 20726694reponame:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVAinstname:INCLIVAInglésinfo:eu-repo/semantics/openAccessoai:incliva.fundanetsuite.com:p42062026-06-07T16:35:31Z
dc.title.none.fl_str_mv HDAC5 Inhibitors as a Potential Treatment in Breast Cancer Affecting Very Young Women
title HDAC5 Inhibitors as a Potential Treatment in Breast Cancer Affecting Very Young Women
spellingShingle HDAC5 Inhibitors as a Potential Treatment in Breast Cancer Affecting Very Young Women
Oltra, SS
breast cancer
young women
histone deacetylase
HDAC5 inhibitors
LMK-235
title_short HDAC5 Inhibitors as a Potential Treatment in Breast Cancer Affecting Very Young Women
title_full HDAC5 Inhibitors as a Potential Treatment in Breast Cancer Affecting Very Young Women
title_fullStr HDAC5 Inhibitors as a Potential Treatment in Breast Cancer Affecting Very Young Women
title_full_unstemmed HDAC5 Inhibitors as a Potential Treatment in Breast Cancer Affecting Very Young Women
title_sort HDAC5 Inhibitors as a Potential Treatment in Breast Cancer Affecting Very Young Women
dc.creator.none.fl_str_mv Oltra, SS
Cejalvo, JM
Tormo, E
Albanell, M
Ferrer, A
Nacher, M
Bermejo, B
Hernando, C
Chirivella, I
Alonso, E
Burgues, O
Pena-Chilet, M
Eroles, P
Lluch, A
Ribas, G
Martinez, MT
author Oltra, SS
author_facet Oltra, SS
Cejalvo, JM
Tormo, E
Albanell, M
Ferrer, A
Nacher, M
Bermejo, B
Hernando, C
Chirivella, I
Alonso, E
Burgues, O
Pena-Chilet, M
Eroles, P
Lluch, A
Ribas, G
Martinez, MT
author_role author
author2 Cejalvo, JM
Tormo, E
Albanell, M
Ferrer, A
Nacher, M
Bermejo, B
Hernando, C
Chirivella, I
Alonso, E
Burgues, O
Pena-Chilet, M
Eroles, P
Lluch, A
Ribas, G
Martinez, MT
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv breast cancer
young women
histone deacetylase
HDAC5 inhibitors
LMK-235
topic breast cancer
young women
histone deacetylase
HDAC5 inhibitors
LMK-235
description Background: Breast cancer in very young women (BCVY) defined as <35 years old, presents with different molecular biology than in older patients. High HDAC5 expression has been associated with poor prognosis in breast cancer (BC) tissue. We aimed to analyze HDAC5 expression in BCVY and older patients and their correlation with clinical features, also studying the potential of HDAC5 inhibition in BC cell lines. Methods: HDAC5 expression in 60 BCVY and 47 older cases were analyzed by qRT-PCR and correlated with clinical data. The effect of the HDAC5 inhibitor, LMK-235, was analyzed in BC cell lines from older and young patients. We performed time and dose dependence viability, migration, proliferation, and apoptosis assays. Results: Our results correlate higher HDAC5 expression with worse prognosis in BCVY. However, we observed no differences between HDAC5 expression and pathological features. Our results showed greatly reduced progression in BCVY cell lines and also in all triple negative subtypes when cell lines were treated with LMK-235. Conclusions: In BCVY, we found higher expression of HDAC5. Overexpression of HDAC5 in BCVY correlates with lower survival rates. LMK-235 could be a potential treatment in BCVY.
publishDate 2020
dc.date.none.fl_str_mv 2020
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://incliva.portalinvestigacion.com/publicaciones/4206
url https://incliva.portalinvestigacion.com/publicaciones/4206
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv Cancers
ISSN: 20726694
reponame:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname:INCLIVA
instname_str INCLIVA
reponame_str r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
collection r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869403560727281664
score 15.811543

Similares en LA Referencia